JPWO2020188570A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020188570A5 JPWO2020188570A5 JP2021556491A JP2021556491A JPWO2020188570A5 JP WO2020188570 A5 JPWO2020188570 A5 JP WO2020188570A5 JP 2021556491 A JP2021556491 A JP 2021556491A JP 2021556491 A JP2021556491 A JP 2021556491A JP WO2020188570 A5 JPWO2020188570 A5 JP WO2020188570A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- polypeptide
- domain
- cells
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962820357P | 2019-03-19 | 2019-03-19 | |
| US62/820,357 | 2019-03-19 | ||
| PCT/IL2020/050327 WO2020188570A1 (fr) | 2019-03-19 | 2020-03-19 | Lymphocyte t exprimant un récepteur fc gamma et procédés d'utilisation correspondants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022525927A JP2022525927A (ja) | 2022-05-20 |
| JPWO2020188570A5 true JPWO2020188570A5 (fr) | 2023-03-27 |
Family
ID=72519182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556491A Pending JP2022525927A (ja) | 2019-03-19 | 2020-03-19 | Ｆｃガンマ受容体を発現するｔ細胞およびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210401893A1 (fr) |
| EP (1) | EP3941492A4 (fr) |
| JP (1) | JP2022525927A (fr) |
| CN (1) | CN113853205A (fr) |
| AU (1) | AU2020243623A1 (fr) |
| CA (1) | CA3133037A1 (fr) |
| IL (1) | IL286477A (fr) |
| WO (1) | WO2020188570A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023530182A (ja) | 2020-06-22 | 2023-07-13 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | 多重サブユニットタンパク質モジュール、それを発現する細胞、及びその使用 |
| WO2024154122A1 (fr) | 2023-01-18 | 2024-07-25 | Gilboa Therapeutics LTD | Cellules immunitaires exprimant un récepteur du complément et leurs utilisations |
| CN117660500A (zh) * | 2023-09-28 | 2024-03-08 | 上海恩凯细胞技术有限公司 | 核酸构建体、载体、转基因免疫细胞及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641863A (en) * | 1993-09-30 | 1997-06-24 | University Of Pennsylvania | Chimeric IgG Fc receptors |
| DK2112162T3 (da) * | 2004-07-10 | 2015-02-23 | Fox Chase Cancer Ct | Genetisk modificerede humane naturlige dræbercellelinjer |
| US10144770B2 (en) * | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| WO2015179833A1 (fr) * | 2014-05-23 | 2015-11-26 | The Trustees Of The University Of Pennsylvania | Compositions et méthodes de traitement d'une résistance aux anticorps |
| AU2015317608B2 (en) * | 2014-09-17 | 2021-03-11 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| EP3268394B1 (fr) * | 2015-03-13 | 2020-05-27 | University of Maryland, Baltimore | Biocapteur à médiation par anticorps universel |
-
2020
- 2020-03-19 WO PCT/IL2020/050327 patent/WO2020188570A1/fr unknown
- 2020-03-19 AU AU2020243623A patent/AU2020243623A1/en active Pending
- 2020-03-19 CA CA3133037A patent/CA3133037A1/fr active Pending
- 2020-03-19 EP EP20774261.0A patent/EP3941492A4/fr active Pending
- 2020-03-19 CN CN202080037294.9A patent/CN113853205A/zh active Pending
- 2020-03-19 JP JP2021556491A patent/JP2022525927A/ja active Pending
-
2021
- 2021-09-19 US US17/478,930 patent/US20210401893A1/en active Pending
- 2021-09-19 IL IL286477A patent/IL286477A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11732052B2 (en) | Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine | |
| AU2019243448B2 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| US12076378B2 (en) | Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors | |
| Hombach et al. | A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA | |
| EP4400516A1 (fr) | Récepteur antigénique chimérique bispécifique ou-grille sensible à cd19 et cd20 | |
| JP2023518049A (ja) | 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体 | |
| JP2024062986A (ja) | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 | |
| JP2019527680A (ja) | 改善された養子ｔ細胞療法 | |
| Urbanska et al. | Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells | |
| JP2024023228A5 (fr) | ||
| KR20180083868A (ko) | 종양 형질도입용 조성물 및 방법 | |
| CN113698490B (zh) | 靶向cea的缺氧诱导启动的car结构及免疫细胞和应用 | |
| EP1413316A1 (fr) | Conjugués bifonctionnels ou protéines de fusions | |
| Moon et al. | Development of bispecific antibody for cancer immunotherapy: focus on T cell engaging antibody | |
| EP3568466A1 (fr) | Lymphocytes t ciblés présentant une cytotoxicité vis-à-vis de cellules immunosuppressives | |
| Vyas et al. | Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer | |
| JPWO2019157533A5 (fr) | ||
| Goebeler et al. | Bispecific and multispecific antibodies in oncology: opportunities and challenges | |
| JPWO2020188570A5 (fr) | ||
| JPWO2021258016A5 (fr) | ||
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| Pfeifer Serrahima et al. | Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies | |
| WO2024121414A1 (fr) | Récepteur antigénique chimérique | |
| JP2024540359A (ja) | Ｔｅａｍを分泌する抗メソテリンｃａｒｔ細胞とその使用方法 | |
| RU2020112538A (ru) | Варианты интерлейкина-18 и способы их применения |